BACKGROUND: Although recent reports indicate that K-ras mutation status is a biomarker that acts as a prognostic factor, only a few analyses of K-ras mutation subtypes have been published. In addition, there are no reports that analyze overall survival and prognostic factors according to K-ras mutation status and subtypes in only unresectable pancreatic cancer (PC) determined from tissues obtained by endoscopic ultrasound-guided fine-needle aspiration. METHODS: We retrospectively analyzed 242 patients who were diagnosed as having unresectable PC with available histological diagnosis. Clinical data collected included sex, age, Eastern Cooperative Oncology Group performance status, carbohydrate antigen (CA) 19-9, primary tumor location, stage (local or metastatic) according to TNM staging, first-line chemotherapy, K-ras mutation status and subtypes (G12D, G12V, and G12R), and overall survival. We analyzed the negative prognostic factors for reduced overall survival in unresectable PC patients using these data. RESULTS: From multivariate analysis, CA19-9 ≥1000 U/ml (hazard ratio [HR] 1.78, 95 % confidence interval [CI] 1.28-2.46, P < 0.01), metastatic stage (HR 2.26, 95 % CI 1.58-3.24, P < 0.01), and mutant-K-ras (HR 1.76, 95 % CI 1.03-3.01, P = 0.04) were negative prognostic factors, indicating a reduced survival. Among the patients who had K-ras mutation subtypes, CA19-9 ≥1000 U/ml (HR 1.65, 95 % CI 1.12-2.37, P < 0.01), metastatic stage (HR 2.12, 95 % CI 1.44-3.14, P < 0.01), and the presence of the G12D or G12R mutations (HR 1.60, 95 % CI 1.11-2.28) were negative prognostic factors for overall survival. CONCLUSIONS: K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients.
BACKGROUND: Although recent reports indicate that K-ras mutation status is a biomarker that acts as a prognostic factor, only a few analyses of K-ras mutation subtypes have been published. In addition, there are no reports that analyze overall survival and prognostic factors according to K-ras mutation status and subtypes in only unresectable pancreatic cancer (PC) determined from tissues obtained by endoscopic ultrasound-guided fine-needle aspiration. METHODS: We retrospectively analyzed 242 patients who were diagnosed as having unresectable PC with available histological diagnosis. Clinical data collected included sex, age, Eastern Cooperative Oncology Group performance status, carbohydrate antigen (CA) 19-9, primary tumor location, stage (local or metastatic) according to TNM staging, first-line chemotherapy, K-ras mutation status and subtypes (G12D, G12V, and G12R), and overall survival. We analyzed the negative prognostic factors for reduced overall survival in unresectable PC patients using these data. RESULTS: From multivariate analysis, CA19-9 ≥1000 U/ml (hazard ratio [HR] 1.78, 95 % confidence interval [CI] 1.28-2.46, P < 0.01), metastatic stage (HR 2.26, 95 % CI 1.58-3.24, P < 0.01), and mutant-K-ras (HR 1.76, 95 % CI 1.03-3.01, P = 0.04) were negative prognostic factors, indicating a reduced survival. Among the patients who had K-ras mutation subtypes, CA19-9 ≥1000 U/ml (HR 1.65, 95 % CI 1.12-2.37, P < 0.01), metastatic stage (HR 2.12, 95 % CI 1.44-3.14, P < 0.01), and the presence of the G12D or G12R mutations (HR 1.60, 95 % CI 1.11-2.28) were negative prognostic factors for overall survival. CONCLUSIONS:K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancerpatients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Woong Sub Koom; Jinsil Seong; Yong Bae Kim; Hae Ok Pyun; Si Young Song Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-28 Impact factor: 7.038
Authors: F Vega; P Iniesta; T Caldes; A Sanchez; J Lopez; C Dejuan; E Diazrubio; A Torres; J Balibrea; M Benito Journal: Int J Oncol Date: 1996-12 Impact factor: 5.650
Authors: Barbara Bournet; Marion Gayral; Jérôme Torrisani; Janick Selves; Pierre Cordelier; Louis Buscail Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Stephan Kruger; Michael Haas; Steffen Ormanns; Sibylle Bächmann; Jens T Siveke; Thomas Kirchner; Volker Heinemann; Stefan Boeck Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Stefan Boeck; Andreas Jung; Rüdiger P Laubender; Jens Neumann; Rosalind Egg; Clara Goritschan; Steffen Ormanns; Michael Haas; Dominik P Modest; Thomas Kirchner; Volker Heinemann Journal: J Gastroenterol Date: 2013-02-23 Impact factor: 7.527
Authors: Jean-Luc Van Laethem; Hanno Riess; Jacek Jassem; Michael Haas; Uwe M Martens; Colin Weekes; Marc Peeters; Paul Ross; John Bridgewater; Bohuslav Melichar; Stefano Cascinu; Piotr Saramak; Patrick Michl; David Van Brummelen; Alberto Zaniboni; Wollf Schmiegel; Svein Dueland; Marius Giurescu; Vittorio L Garosi; Katrin Roth; Anke Schulz; Henrik Seidel; Prabhu Rajagopalan; Michael Teufel; Barrett H Childs Journal: Target Oncol Date: 2017-02 Impact factor: 4.493
Authors: Vicente Valero; Tyler J Saunders; Jin He; Matthew J Weiss; John L Cameron; Avani Dholakia; Aaron T Wild; Eun Ji Shin; Mouen A Khashab; Anne Marie O'Broin-Lennon; Syed Z Ali; Daniel Laheru; Ralph H Hruban; Christine A Iacobuzio-Donahue; Joseph M Herman; Christopher L Wolfgang Journal: Ann Surg Date: 2016-01 Impact factor: 12.969